Drug Channels

MAY 25, 2021

This Feed is for personal non-commercial use only. Summer unofficially begins this weekend! P.S. Join the nearly 11,800 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also follow me on LinkedIn. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 52

Pharmacy Drugs Marketing 52

Pharmaceutical Technology

MAY 9, 2023

“Xylazine started showing up in the dope in Philadelphia around 2010 and recently started to spread across the US, says Jon Zibbell, PhD, a senior public health scientist at RTI International, a non-profit research institute in North Carolina that provides data and analysis to inform public policy.” Fact box: What is tranq?

Drugs 278

Drugs Regulation Containment Scientist 278

Drug Channels

OCTOBER 15, 2020

Last week, news broke that Prime Therapeutics is expanding its relationship with Cigna’s Express Scripts to include mail and specialty pharmacy dispensing. Once again, channel intermediaries continue to gain power and extract profits. This Feed is for personal non-commercial use only. More to come.

Pharmacy 52

Pharmacy Drugs Marketing 52

Drug Channels

OCTOBER 20, 2020

In upcoming articles, I’ll examine how chain and independent pharmacies will participate in these plans and what that means for pharmacy profits. As always, Drug Channels brings you the news—so you don't have to get it yourself. This Feed is for personal non-commercial use only. d/b/a Drug Channels Institute.

Pharmacy 52

Pharmacy Drugs 52

Drug Channels

DECEMBER 14, 2020

Last week, news broke that Prime Therapeutics is expanding its relationship with Cigna’s Express Scripts to include mail and specialty pharmacy dispensing. Once again, channel intermediaries continue to gain power and extract profits. This Feed is for personal non-commercial use only. More to come.

Pharmacy 52

Pharmacy Drugs Marketing 52

Drug Channels

DECEMBER 10, 2020

This Feed is for personal non-commercial use only. Well, we are almost finished with 2020. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Vaccination Vaccine Drugs 52

XTalks

MAY 7, 2021

We have all heard of non-dairy and 100 percent vegan ice cream made of coconut, soy and almond milks, but for the first time, Wildgood has introduced vegan ice cream made with extra virgin olive oil. The company delivers its extra virgin olive oil-based non-dairy ice cream directly to consumers’ doors nationwide.

Containment 59

Containment Branding Protein Development 59

Drug Channels

FEBRUARY 23, 2021

Let’s melt away this foul February with our monthly selection of scorching news from around the drug channel. Humana’s fully insured commercial and ASO medical membership accounted for just under 12% of its non-military medical membership as of December 31, 2020. The paper also shows a non-340B example.). Click to Enlarge].

Pharmacy 52

Pharmacy Drugs Generic Drugs Production 52

pharmaphorum

MARCH 3, 2021

After her daughter, Iris, was diagnosed with a rare disease at five, friends, family, and strangers donated so much to a research fund-raising campaign that she had to set up a non-profit to deal with it all. They usually pass away from complications. It was completely unexpected. Hope on the horizon.

Gene Therapy 125

Gene Therapy Clinical Trials Clinical Trials Gene 125

XTalks

FEBRUARY 2, 2023

People affected by diabetes, their caregivers and healthcare providers are the pillars of the non-profit organization Tidepool. We look forward to continuing to work with Tidepool to make open protocol a reality, and we anxiously await news on future AID systems that will utilize this tremendous platform,” added Kowalski.

Insulin 52

Insulin Marketing Life Science Development 52

Drug Discovery World

DECEMBER 27, 2023

You can tune in every week to DDW Highlights for a roundup of industry news and updates. Dr. Samulski’s graduate work demonstrated the first substrate for adeno-associated viruses (AAV) as a viral vector and culminated in the first US patent involving non-AAV genes inserted into AAV. Episodes are released weekly.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

pharmaphorum

JULY 1, 2022

The agreements provide the company with additional cash without the dilutive effect of other financing measures in what is currently a challenging market, but the company’s shares dipped on the news, possibly they reduce the likelihood of a takeover of Blueprint by a larger company.

Business Development 52

Business Development Medicine Sales Marketing 52

Triage Cancer

MARCH 23, 2021

As a 501(c)(3) charitable non-profit organization based in Washington, D.C, NAC founded the International Alliance of Carer Organizations (IACO), a global coalition that includes 16 non-governmental organizations. system of social and economic programs, policies, and resources) providing all of the above-mentioned supports. .

Research 52

Research Nurses 52

XTalks

FEBRUARY 21, 2022

The German company announced the plans at a meeting that took place last week at its new manufacturing facility in Marburg, Germany. The company was invited by the kENUP Foundation, a non-profit public benefit organization that is representing BioNTech, with attendees that included BioNTech’s co-founders Prof. ahin, CEO; Prof.

Vaccination 105

Vaccination Vaccine Production Manufacturing 105

XTalks

MAY 4, 2023

Overall, the state of clinical trials for celiac disease is promising, as researchers are actively working to develop new treatments that could help improve the lives of people with the condition. What are some barriers that patients with celiac disease voice about participating in clinical trials for non-dietary therapies?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

pharmaphorum

FEBRUARY 1, 2022

After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to market to treat the liver disease non-alcoholic steatohepatitis (NASH). Investors seem to still be hesitant. The post Madrigal sings praises of NASH drug resmetirom appeared first on.

Drugs 52

Drugs Marketing Hormones Trials 52

pharmaphorum

FEBRUARY 18, 2022

This should be fantastic news for the rapidly growing sector, but lack of equal access is proving to be a fly in the ointment. In the United States, a new coalition of non-profit, academic, and industry players is taking a collaborative stand against inequitable access.

Doctors 106

Doctors Doctor 106

pharmaphorum

AUGUST 28, 2020

Shares in dermatology specialist Cassiopea, which is listed on the SWX exchange in Switzerland, rose almost 17% after news of the FDA approval emerged. By locally blocking androgens, Winlevi prevents the production of excess oil (sebum) and dampens down inflammation, according to the company.

Dermatology 52

Dermatology Drugs Hormones FDA Approval 52

The Pharma Data

AUGUST 3, 2021

Non-GAAP EPS increased 4% to $4.38 Non-GAAP operating income decreased 4% to $3.1 billion and non-GAAP operating margin decreased 4.1 on a non-GAAP basis. on a non-GAAP basis. Refer to Non-GAAP Financial Measures below for further discussion. GAAP operating income decreased 64% to $0.8

Sales 52

Sales Production Antibody Development 52

The Pharma Data

JANUARY 24, 2021

As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously announced on November 4, 2020, that it would retain 50% of the revenue and profit from the sale of its rapid antigen test through Torion Biosciences Inc. (“Torion”).

Sales 52

Sales Manufacturing Contract Manufacturing Containment 52

XTalks

APRIL 26, 2021

In October 2019, the Denver, Colorado-based UFA launched as a non-profit and accumulated around 70 members in the first six months. In return, the UFA offers the use of its marker as well as exclusive research and industry news, networking opportunities, educational and promotional tools, media coverage, sales support and more.

Packaging 59

Packaging Packaging Production Branding 59

The Pharma Data

OCTOBER 30, 2020

Technical expertise is being provided by First Draft , a non-profit that works globally to tackle misinformation. . The training programme has been driven by a recognition of the harm being caused by false and misleading health information circulating in online spaces, low quality news outlets and in peer to peer discussions.

52

52

Pharmacy Checkers

FEBRUARY 28, 2020

Yesterday, I was asked by Ed Silverman of STAT NEWS’ Pharmalot. As we know from the debate on drug importation, the pharmaceutical industry wants to have maximum control over the distribution of its products in a manner maximizing its profits. That narrative holds that any non-U.S. wholesale pharmacy $80,000. is “illegitimate.”.

Pharmacy 55

Pharmacy Drugs Sales Compliance 55

Delveinsight

JULY 28, 2020

Daiichi’s DS-1062 , a trophoblast cell-surface antigen 2 (TROP2) directed DXd antibody-drug conjugate (ADC) is currently in Phase I clinical trial for multiple cancer types including the majority of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Gene Therapy 52

Gene Therapy Trials Gene Vaccination 52

pharmaphorum

SEPTEMBER 18, 2020

“Picking the next merger candidate is hard enough, doing so before everyone else jumps on board, then picking the right time to sell makes for a dangerous investment game,” said one BBC News article from December 1998. The EU patents expired in 2010 and 2011, causing further profit loss. Pfizer makes its move.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

Delveinsight

FEBRUARY 5, 2021

From non-existent to a routine, then a trend, and over the time cigarette smoking became nothing but a nuisance that the whole world is fighting. However, it seems the mass-campaigns led by international organizations and non-profit organizations managed to evoke awareness among people. Smoking Cessation Emerging Therapies.

Marketing 52

Marketing FDA Approval Branding Production 52

pharmaphorum

APRIL 7, 2021

He spoke to pharmaphorum’s news editor Richard Staines to outline his plans to create a European biotech powerhouse. . But now the company is profitable and on a sound financial footing there is much more room for negotiation, van de Winkel said. The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories.

Antibody 64

Antibody Life Science Development Regulation 64

The Pharma Data

NOVEMBER 20, 2020

As Pfizer and BioNTech announced news of a possible Covid-19 vaccine on November 8 , in haste, pharma leaders are rallying to ensure supply chains will be able to support distribution. However, concerns from 500+ supply chain professionals reveals concerns about a lack of resilience as many prepare for third wave of Covid-19 infections.

Drugs 52

Drugs Pharma Companies Vaccination Vaccine 52

The Pharma Data

APRIL 30, 2021

net revenues of $999 million and international profit sharing of $269 million. per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items. Non-GAAP Financial Results. d Reflects profit sharing for Imbruvica international revenues. About AbbVie.

Botox 40

Botox Production Development Cosmetics 40

The Pharma Data

NOVEMBER 17, 2021

High and upper-middle income countries will pay further than lower income countries, which will pay a not-for- profit price. This press release features multimedia.

Licensing 52

Licensing Licensing Medicine Manufacturing 52

The Pharma Data

OCTOBER 28, 2020

. “We recognize there is more work to be done, and the team is operating with urgency to deliver on our growth drivers and strategic priorities, including advancing our pipeline and improving profitability and cash generation. Constant-currency percent change is considered a non-GAAP metric. (11.2.

Sales 40

Sales Production Compliance Marketing 40

Rethinking Clinical Trials

FEBRUARY 22, 2023

The study is enrolling people where they are using social media, such as Facebook ads, twitter influencers, tv ads, interviews with print/electronic news outlets, national tv (an appearance on “The Talk” to discuss the study), targeted advertising, physicians, electronic health records. There was news pushed out about general health.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Nurses 130

pharmaphorum

AUGUST 13, 2020

Non-pharma brands leading by example. New York Magazine , the New York Times and The Economist amongst many other news organisations knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment. Something was broken before COVID-19 came along.

Branding 83

Branding Vaccination Vaccine Filler 83

pharmaphorum

DECEMBER 23, 2022

The US regulator has approved Lunsumio (mosunetuzumab) for the same indication – patients who have previously been treated with two or more lines of systemic therapy – making it the first CD20xCD3 bispecific to be authorised for this form of non-Hodgkin lymphoma (NHL).

Antibody 88

Antibody Sales Drugs Trials 88

pharmaphorum

JUNE 8, 2022

The European Commission has approved mosunetuzumab under the Lunsumio trade name for relapsed or refractory FL, the most common slow-growing form of non-Hodgkin lymphoma (NHL), after two or more prior systemic therapies. The approval, meanwhile, raises expectations of a positive outcome from the FDA as it reviews the drug for the US market.

Sales 103

Sales Antibody Licensing Licensing 103

XTalks

OCTOBER 5, 2021

The patients were non-hospitalized. A pill for COVID-19, particularly for mild to moderate COVID-19, is welcome news as it could give patients a simple, non-invasive treatment option that they may be more inclined to take. Gilead’s antiviral remdesivir is administered intravenously for the treatment of hospitalized patients.

Trials 96

Trials Vaccination Vaccine Drugs 96

pharmaphorum

APRIL 25, 2022

The drug has been recommended by the CHMP for approval as Lunsumio as a since-agent treatment for relapsed or refractory follicular lymphoma (FL), a form of non-Hodgkin lymphoma (NHL), after two or more prior systemic therapies. It is also in line for low single-digit royalties on sales elsewhere. Tecentriq as adjuvant NSCLC therapy.

Sales 52

Sales Marketing Medicine Genetics 52